The patent – no. 13/132,475 – covers technology that can freeze and thereby extend the shelf life of the neural, retinal and mesenchymal cells according to Reneuron.
A spokesman told us the technology is used to “freeze the cells in order that they can be readily shipped and stored with a long shelf life” adding that “they are then thawed at the site and administered when required.”
Reneuron said the tech in question is a “formulation” but did not go into additional details.
The spokesman did say that: “We have developed our own formulation which is optimal for our cells and avoids the need for toxic cryopreservants typically found in marketed solutions.”
Reneuron has used the technology to develop an extended shelf life version of its ischemic stroke therapy – CTX stem cell. The developmental therapy is made at Reneuron's facility in Pencoed, Wales and distributed to clinical trial sites across the UK.
Last August, the firm installed new processing technology to automate production of CTX ahead of late phase trials. The cryopreservation technology covered by the new US patent is a further effort to streamline the manufacturing process.
However, the US patent does open up other possibilities for Reneruon beyond protecting its own cell therapy products.
The firm’s spokesman told us “The primary purpose of the patent is to protect our technology assets. Should a third party wish to utilise the technology, we would consider granting licenses on a case-by-case basis.”